TY  - JOUR 
AU  - Redondo, A. M.
AU  - Valcárcel, D.
AU  - González-Rodríguez, A. P.
AU  - Suárez-Lledó, M.
AU  - Bello López, José Luis
AU  - Canales, M.
AU  - Gayoso, J.
AU  - Colorado, M.
AU  - Jarque, I.
AU  - del Campo, R.
AU  - Arranz, R.
AU  - Terol, M. J.
AU  - Rifón, J. J.
AU  - Rodríguez, M. J.
AU  - Ramírez, M. J.
AU  - Castro, N.
AU  - Sánchez, A.
AU  - López-Jiménez, J.
AU  - Montes-Moreno, S.
AU  - Briones, J.
AU  - López, A.
AU  - Palomera, L.
AU  - López-Guillermo, A.
AU  - Caballero, D.
AU  - Martín, A.
PY  - 2019
SN  - 0007-1048
UR  - http://hdl.handle.net/20.500.11940/15783
AB  - We conducted a phase 2 trial to evaluate the safety and efficacy of bendamustine instead of BCNU (carmustine) in the BEAM (BCNU, etoposide, cytarabine and melphalan) regimen (BendaEAM) as conditioning for autologous stem-cell transplantation (ASCT) in...
LA  - eng
KW  - Adult
KW  - Melphalan
KW  - Middle Aged
KW  - Podophyllotoxin
KW  - Autografts
KW  - Survival Rate
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Cytarabine
KW  - Peripheral Blood Stem Cell Transplantation
KW  - Humans
KW  - Disease-Free Survival
KW  - Transplantation Conditioning
KW  - Lymphoma
KW  - Aged
KW  - Carmustine
TI  - Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group
DO  - 10.1111/bjh.15713
T2  - BRITISH JOURNAL OF HAEMATOLOGY
M2  - 797
KW  - CHUS
VL  - 184
ER  -